PCRX Pacira BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCRX

Price (delayed)

$39.14

Market cap

$1.8B

P/E Ratio

111.83

Dividend/share

N/A

EPS

$0.35

Enterprise value

$2.46B

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights
Pacira BioSciences's debt has decreased by 32% YoY and by 7% from the previous quarter
The revenue has grown by 23% YoY
The company's quick ratio has surged by 82% YoY but it fell by 18% QoQ
Pacira BioSciences's gross profit has increased by 17% YoY but it has decreased by 2.1% QoQ
Pacira BioSciences's EPS has shrunk by 63% YoY and by 22% QoQ
The company's net income has shrunk by 62% YoY and by 24% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.pacira.com
Peers: DRRX HRTX CARA CPIX

Key stats

What are the main financial stats of PCRX
Market
Shares outstanding
45.95M
Market cap
$1.8B
Enterprise value
$2.46B
Valuations
Price to earnings (P/E)
111.83
Price to book (P/B)
2.32
Price to sales (P/S)
2.67
EV/EBIT
46.13
EV/EBITDA
16.98
EV/Sales
3.69
Earnings
Revenue
$666.82M
EBIT
$53.28M
EBITDA
$144.78M
Free cash flow
$115.2M
Per share
EPS
$0.35
Free cash flow per share
$2.53
Book value per share
$16.89
Revenue per share
$14.65
TBVPS
$21.47
Balance sheet
Total assets
$1.68B
Total liabilities
$906.19M
Debt
$763.39M
Equity
$775.01M
Working capital
$350.56M
Liquidity
Debt to equity
0.99
Current ratio
3.37
Quick ratio
2.62
Net debt/EBITDA
4.55
Margins
EBITDA margin
21.7%
Gross margin
70.1%
Net margin
2.4%
Operating margin
9%
Efficiency
Return on assets
0.9%
Return on equity
2.1%
Return on invested capital
3.4%
Return on capital employed
3.5%
Return on sales
8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
1.4%
1 week
-0.89%
1 month
-4.54%
1 year
-48.23%
YTD
1.37%
QTD
1.37%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$666.82M
Gross profit
$467.53M
Operating income
$60.02M
Net income
$15.91M
Gross margin
70.1%
Net margin
2.4%
Pacira BioSciences's net margin has plunged by 69% YoY and by 25% from the previous quarter
The company's net income has shrunk by 62% YoY and by 24% QoQ
PCRX's operating margin is down by 46% YoY and by 20% QoQ
The company's operating income fell by 33% YoY and by 19% QoQ

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
P/E
111.83
P/B
2.32
P/S
2.67
EV/EBIT
46.13
EV/EBITDA
16.98
EV/Sales
3.69
Pacira BioSciences's EPS has shrunk by 63% YoY and by 22% QoQ
PCRX's P/E is 16% above its last 4 quarters average of 96.1
PCRX's P/B is 47% below its 5-year quarterly average of 4.4 and 32% below its last 4 quarters average of 3.4
The equity has increased by 6% year-on-year
The price to sales (P/S) is 46% lower than the 5-year quarterly average of 4.9 and 35% lower than the last 4 quarters average of 4.1
The revenue has grown by 23% YoY

Efficiency

How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROA has plunged by 68% YoY and by 18% from the previous quarter
PCRX's ROE has dropped by 65% year-on-year and by 25% since the previous quarter
Pacira BioSciences's return on sales has shrunk by 51% YoY and by 19% QoQ
Pacira BioSciences's ROIC has decreased by 48% YoY and by 19% from the previous quarter

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 86% greater than the total liabilities
The current ratio has soared by 103% YoY but it has contracted by 17% from the previous quarter
The company's quick ratio has surged by 82% YoY but it fell by 18% QoQ
Pacira BioSciences's debt to equity has decreased by 36% YoY and by 7% from the previous quarter
Pacira BioSciences's debt has decreased by 32% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.